| __timestamp | Blueprint Medicines Corporation | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 10337679 |
| Thursday, January 1, 2015 | 14456000 | 18187286 |
| Friday, January 1, 2016 | 19218000 | 24758063 |
| Sunday, January 1, 2017 | 27986000 | 23666957 |
| Monday, January 1, 2018 | 47928000 | 30099855 |
| Tuesday, January 1, 2019 | 96388000 | 64947625 |
| Wednesday, January 1, 2020 | 157743000 | 186363444 |
| Friday, January 1, 2021 | 195293000 | 272611040 |
| Saturday, January 1, 2022 | 237374000 | 358782000 |
| Sunday, January 1, 2023 | 295141000 | 409864000 |
| Monday, January 1, 2024 | 359272000 |
Unveiling the hidden dimensions of data
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two pioneering companies: Intra-Cellular Therapies, Inc. and Blueprint Medicines Corporation, from 2014 to 2023. Over this period, Intra-Cellular Therapies, Inc. saw a staggering increase in SG&A expenses, growing nearly 40 times from 2014 to 2023. Blueprint Medicines Corporation also experienced a significant rise, with expenses increasing by approximately 37 times. This upward trend reflects the companies' aggressive strategies in research, development, and market expansion. Notably, by 2023, Intra-Cellular Therapies, Inc.'s SG&A expenses surpassed Blueprint Medicines Corporation by about 39%, highlighting its robust growth trajectory. These insights offer a glimpse into the financial strategies driving innovation in the biotech sector.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Bio-Techne Corporation
Intra-Cellular Therapies, Inc. and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Verona Pharma plc
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Geron Corporation Trends and Insights
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends